# Standard Versus Prolonged-release Tacrolimus Monotherapy After Alemtuzumab Induction in Kidney Transplantation

> **NCT00807144** · PHASE4 · COMPLETED · sponsor: **Imperial College Healthcare NHS Trust** · enrollment: 102 (actual)

## Conditions studied

- End-stage Renal Failure
- Graft Rejection

## Interventions

- **DRUG:** Tacrolimus (Kidney transplant maintenance immunosuppression)
- **DRUG:** Kidney transplant maintenance immunosuppression

## Key facts

- **NCT ID:** NCT00807144
- **Lead sponsor:** Imperial College Healthcare NHS Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2012-03
- **Final completion:** 2012-03
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2021-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00807144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00807144, "Standard Versus Prolonged-release Tacrolimus Monotherapy After Alemtuzumab Induction in Kidney Transplantation". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT00807144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*